• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Ophthalmology

Intra-arterial thrombolysis in central retinal artery occlusion can benefit some patients

byAndrew Bishara
November 1, 2013
in Ophthalmology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

 Image: PD 

1. Among incomplete central retinal artery occlusion (CRAO), those who received thrombolysis had a significant visual acuity improvement at the final visit compared to standard therapy group (0.83 vs. 1.57 logMAR respectively; p=0.020). 

2. Early reperfusion was significantly higher with thrombolysis compared to standard therapy (74.1% vs. 42.9%; p=0.005).

Evidence Rating Level: 2 (Good)

Study Rundown: The appropriate management of retinal occlusive disease has been a longstanding issue. Prior studies had demonstrated that there is no benefit to intra-arterial thrombolysis. However, the prior studies did not evaluate long-term effects of thrombolysis. This South Korean study demonstrates the potential value of thrombolysis in certain types of CRAO, specifically incomplete cases. The data seem to suggest that thrombolysis can significantly improve vision among this group of patients in the long-term. While this conclusion may be clinically important, it is unclear whether the injection of antithrombotic agents into the ophthalmic artery is truly safe and more importantly, cost-effective. No significant adverse effects were reported in this particular study. In addition, the sample size in this study is relatively small (especially the incomplete CRAO group) given its retrospective nature.

Click to read the study in IOVS

Relevant Reading: Central retinal artery occlusion: local intra-arterial fibrinolysis versus conservative treatment, a multicenter randomized trial

RELATED REPORTS

Monthly brolucizumab is noninferior to aflibercept in treating recalcitrant wet age-related macular degeneration

#VisualAbstract Assessing early tumour response and immune-related adverse events when undergoing combination nivolumab and ipilimumab therapy for advanced melanoma

#VisualAbstract Brentuximab Vedotin is a safe and effective treatment in patients with Mycosis Fungoides and Sezary Syndrome

In-Depth [retrospective study]: Patients were grouped on 2 axes – treatment received and extent of central retinal artery occlusion (CRAO). Patients either received intra-arterial thrombolysis (IAT) or standard therapy (ST), which consisted of ocular massage and intraocular pressure reduction. The extent of CRAO was graded into 3 categories – incomplete, subtotal, and total. Division into the IAT and ST groups was dependent on time since onset of symptoms. IAT was performed by injecting urokinase with a microcatheter placed within the ophthalmic artery. Visual acuity (VA) was compared between the IAT & ST groups at one-month and at a final visit months later. Early (prior to 3 days) and final (1 month) rates of reperfusion were also assessed. MRI scans were obtained to identify any intraparenchymal hemorrhage. Initial, 1-month, and final visit VA was not statistically significant between the groups. However, among incomplete CRAO, the IAT group had a significant improvement in VA at the final visit compared to the ST group (0.83 vs. 1.57 logMAR respectively; p=0.020). The percentage of incomplete CRAO patients with VA of better than 20/200 at the final visit was significantly higher with IAT compared to ST (p<0.01). Early reperfusion was significantly higher with IAT compared to ST (74.1% vs. 42.9%; p=0.005). No cerebral hemorrhages were noted with IAT therapy.

By Swarup Swaminathan and Andrew Bishara

More from this author: Argus II retinal prosthesis significantly improves spatial vision in blind patients, Artificial cornea is well retained in patients with ocular surface disease, High prevalence of undiagnosed glaucoma in West Africa, Interferon therapy is superior to methotrexate for uveitis, Rho kinase inhibitor safely reduces intraocular pressure

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: central retinal artery occlusion treatmentintra-arterial thrombolysislong-term efficacyonset of symptomsretrospective studystandard therapyvisual acuity
Previous Post

Saccadic eye movements predictive of surgical resident fatigue

Next Post

Bivalirudin during transport for primary PCI reduces major bleeding

RelatedReports

Nonpowder gun-related pediatric eye injuries on the rise
Ophthalmology

Monthly brolucizumab is noninferior to aflibercept in treating recalcitrant wet age-related macular degeneration

June 7, 2022
#VisualAbstract Assessing early tumour response and immune-related adverse events when undergoing combination nivolumab and ipilimumab therapy for advanced melanoma
StudyGraphics

#VisualAbstract Assessing early tumour response and immune-related adverse events when undergoing combination nivolumab and ipilimumab therapy for advanced melanoma

November 18, 2021
#VisualAbstract Brentuximab Vedotin is a safe and effective treatment in patients with Mycosis Fungoides and Sezary Syndrome
StudyGraphics

#VisualAbstract Brentuximab Vedotin is a safe and effective treatment in patients with Mycosis Fungoides and Sezary Syndrome

June 24, 2021
#VisualAbstract ENESTnd: Frontline nilotinib therapy shows improvement in long-term efficacy outcomes for patients in the chronic phase of newly diagnosed chronic myeloid leukemia
StudyGraphics

#VisualAbstract ENESTnd: Frontline nilotinib therapy shows improvement in long-term efficacy outcomes for patients in the chronic phase of newly diagnosed chronic myeloid leukemia

February 4, 2021
Next Post
Computer more accurate than clinical gestalt in predicting ACS

Bivalirudin during transport for primary PCI reduces major bleeding

High cumulative-dose isotretinoin treatment decreases risk of acne relapse

High cumulative-dose isotretinoin treatment decreases risk of acne relapse

Antepartum and intrapartum events both linked to neonatal HIE

Spontaneous early term delivery associated with subsequent preterm birth

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Tirzepatide Once Weekly for the Treatment of Obesity
  • Wellness Check: Sleep
  • #VisualAbstract: Intravenous vitamin C increases mortality and organ dysfunction in sepsis patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.